No Evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Marcus, Julia L ^a,b   Glidden, David V ^c   Mayer, Kenneth H ^d,e   Liu, Albert Y ^c,f   Buchbinder, Susan P ^c,f   Amico, K Rivet ^g   McMahan, Vanessa ^a   Kallas, Esper Georges ^h   Montoya Herrera, Orlando ⁱ   Pilotto, Jose ^j   Grant, Robert M ^a,c  

^a GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d FENWAY INSTITUTE   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF CONNECTICUT   (United States)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ Fundacion Ecuatoriana Equidad   (Ecuador)

^j HOSPITAL GERAL DE FORTALEZA   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PLACEBO;

ADULT; ANAL INTERCOURSE; ARTICLE; ATTITUDE TO HEALTH; CONDOM USE; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; PREEXPOSURE PROPHYLAXIS; PROPHYLAXIS; RISK ASSESSMENT; SEXUAL BEHAVIOR; SYPHILIS;

ADENINE; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; DEOXYCYTIDINE; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PREGNANCY; SEXUAL BEHAVIOR; TRANSGENDERED PERSONS; YOUNG ADULT;

EID: 84893174696     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081997     Document Type: Article

References (40)

1. UNAIDS (2012) World AIDS Day Report. UNAIDS.
2. Beyrer C, Baral SD, Walker D, Wirtz AL, Johns B, et al. (2010) The expanding epidemics of HIV type 1 among men who have sex with men in low- and middle-income countries: diversity and consistency. Epidemiol Rev 32: 137-151.
3. van Griensven F, de Lind van Wijngaarden JW, Baral S, Grulich A (2009) The global epidemic of HIV infection among men who have sex with men. Current Opin HIV AIDS 4: 300-307.
4. Rotheram-Borus MJ, Swendeman D, Chovnick G (2009) The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol 5: 143-167.
5. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
6. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, et al. (2012) Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 4: 151ra125.
7. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. (2012) Preexposure prophylaxis for HIV infection among African women. N Engl J Med 367: 411-422.
8. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, et al. (2013) Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel int he VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA.
9. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med.
10. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012) Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 367: 423-434.
11. Cassell MM, Halperin DT, Shelton JD, Stanton D (2006) Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 332: 605-607. (Pubitemid 44365764)
12. Eaton LA, Kalichman S (2007) Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 4: 165-172.
13. Adams J (1995) Risk. London: Routledge.
14. Wilde GJS (2001) Target risk: dealing with the danger of death, disease and damage in everyday decisions. Toronto, Ontario: PDE Publications.
15. Richens J, Imrie J, Copas A (2000) Condoms and seat belts: the parallels and the lessons. Lancet 355: 400-403.
16. Autier P, Dore JF, Cattaruzza MS, Renard F, Luther H, et al. (1998) Sunscreen use, wearing clothes, and number of nevi in 6- to 7-year-old European children. European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Natl Cancer Inst 90: 1873-1880.
17. Crepaz N, Hart TA, Marks G (2004) Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 292: 224-236. (Pubitemid 38918000)
18. Vissers DC, Voeten HA, Nagelkerke NJ, Habbema JD, de Vlas SJ (2008) The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One 3: e2077.
19. Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, et al. (2008) Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 22: 1829-1839.
20. Chesney MA, Chambers DB, Kahn JO (1997) Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol 16: 266-271.
21. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2: e298.
22. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369: 657-666.
23. Mattson CL, Campbell RT, Bailey RC, Agot K, Ndinya-Achola JO, et al. (2008) Risk compensation is not associated with male circumcision in Kisumu, Kenya: a multi-faceted assessment of men enrolled in a randomized controlled trial. PLoS One 3: e2443.
24. Kong X, Kigozi G, Nalugoda F, Musoke R, Kagaayi J, et al. (2012) Assessment of changes in risk behaviors during 3 years of posttrial follow-up of male circumcision trial participants uncircumcised at trial closure in Rakai, Uganda. Am J Epidemiol 176: 875-885.
25. Bartholow BN, Buchbinder S, Celum C, Goli V, Koblin B, et al. (2005) HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 39: 90-101. (Pubitemid 40617024)
26. Martin JN, Roland ME, Neilands TB, Krone MR, Bamberger JD, et al. (2004) Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 18: 787-792. (Pubitemid 38535007)
27. Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, et al. (2004) Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 35: 519-525. (Pubitemid 38420661)
28. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, et al. (2007) Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2: e27.
29. Liu AY, Vittinghoff E, Chillag K, Mayer K, Thompson M, et al. (2013) Sexual risk behavior among HIV-uninfected men who have sex with men (MSM) participating in a tenofovir pre-exposure prophylaxis (PrEP) randomized trial in the United States. J Acquir Immune Defic Syndr.
30. Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EE, et al. (2008) Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis 35: 1002-1008.
31. Huebner DM, Gerend MA (2001) The relation between beliefs about drug treatments for HIV and sexual risk behavior in gay and bisexual men. Ann Behav Med 23: 304-312. (Pubitemid 33134837)
32. Festinger L (1957) A theory of cognitive dissonance. Evanston, Ill.: Row Peterson.
33. Higgins DL, Galavotti C, O'Reilly KR, Schnell DJ, Moore M, et al. (1991) Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA 266: 2419-2429.
34. Denison JA, O'Reilly KR, Schmid GP, Kennedy CE, Sweat MD (2008) HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990-2005. AIDS Behav 12: 363-373.
35. Bish A, Michie S (2010) Demographic and attitudinal determinants of protective behaviours during a pandemic: a review. Br J Health Psychol 15: 797-824.
36. Kasparian NA, McLoone JK, Meiser B (2009) Skin cancer-related prevention and screening behaviors: a review of the literature. J Behav Med 32: 406-428.
37. Brewer NT, Chapman GB, Gibbons FX, Gerrard M, McCaul KD, et al. (2007) Meta-analysis of the relationship between risk perception and health behavior: the example of vaccination. Health Psychol 26: 136-145. (Pubitemid 46494598)
38. Herbst JH, Jacobs ED, Finlayson TJ, McKleroy VS, Neumann MS, et al. (2008) Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav 12: 1-17. (Pubitemid 351143456)
39. Mustanski BS, Newcomb ME, Du Bois SN, Garcia SC, Grov C (2011) HIV in young men who have sex with men: a review of epidemiology, risk and protective factors, and interventions. J Sex Res 48: 218-253.
40. Sarkar NN (2008) Barriers to condom use. Eur J Contracept Reprod Health Care 13: 114-122.